This webinar discussed the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers.

Our expert panel — Gregory Tsongalis from Dartmouth-Hitchcock, Anthony Magliocco from Moffitt Cancer Center, Ravindra Kolhe from Augusta University, and Rakesh Nagarajan from PierianDx — specifically discuss their experiences with Illumina’s TruSight Tumor 170 targeted cancer assay.

The TST170 next-generation sequencing-based panel targets single nucleotide variants, indels, gene amplifications, gene fusions, splice variants, mRNA expression, and mRNA isoform detection found in 170 cancer-related genes and also calculates metrics such as tumor mutation burden and determines evidence for microsatellite instability.

Our panelists discuss the design of the assay, data analytics, and reasons behind their selection of the TST170 assay, and share details of how it is being utilized within their organizations.